Status:
RECRUITING
Metastases Directed Therapy for Oligometastatic Breast Cancer
Lead Sponsor:
National Cancer Institute, Egypt
Conditions:
Breast Cancer
Metastatic Cancer
Eligibility:
FEMALE
18-70 years
Phase:
NA
Brief Summary
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometa...
Detailed Description
Objectives: Primary objectives: • Assessment of the outcome (progression free survival) of patients with extracranial oligometastatic breast cancer receiving standard of care systemic treatment comp...
Eligibility Criteria
Inclusion
- Female patients aged 18 to 70 years.
- Pathological evidence of breast cancer, any grade, any T stage.
- Radiological (at least) evidence of metastatic activity with maximum number of 5 extracranial lesions.
- Performance status ≤ 2
- No pre-existing conditions that may prohibit radiotherapy.
Exclusion
- •.Pregnant and lactating women.
- Prior radiotherapy to affected site(s) in less than a year.
- Active Connective tissue diseases (e.g Rheumatoid Arthritis).
- Progression to widespread metastatic disease
- Cases with brain metastasis
Key Trial Info
Start Date :
September 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 20 2028
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06144346
Start Date
September 20 2023
End Date
September 20 2028
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Cairo, Egypt, 11796